Previous studies estimated that prostate-specific membrane antigen positron emission tomography/computed tomography is likely to be cost saving compared with conventional imaging.

An 18 F-fluorodeoxyglucose positron emission tomography response-adapted treatment strategy could lead to improved quality of life for some patients with HER2-positive, early-stage breast cancer, study findings indicate.

medwireNews : Postprostatectomy salvage radiotherapy guided by 18 F-fluciclovine-positron emission tomography (PET)–computed tomography (CT) is associated with improved outcomes relative to that guided by conventional imaging, research suggests.

Use of positron emission tomography–computed tomography before diagnosis is associated with increased receipt of stage-appropriate treatment and decreased mortality among veterans with non-small-cell lung cancer, research suggests.

They add: “The toxicity was modest, suggesting that concerns about toxicity from twice-daily thoracic radiotherapy might be unjustified when using modern radiotherapy techniques and limiting radiotherapy fields to PET-CT [positron emission tomography-computed tomography] positive lesions.”

Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18 F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.

medwireNews : The US FDA has permitted the use of 68 gallium-labeled prostate-specific membrane antigen (68Ga-PSMA-11) as a tracer for positron emission tomography (PET) to detect prostate cancer metastases or recurrence.

Target volume reduction based on 18 F-fluorodeoxyglucose positron emission tomography may be superior to conventional target volume planning for local control in patients with locally advanced non-small-cell lung cancer, research shows.

The majority were staged before treatment using positron emission tomography.

medwireNews : 68 Ga-prostate-specific membrane antigen (PSMA)-11 should be the “tracer of choice” for positron emission tomography–computed tomography (PET–CT) to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.

Positron emission tomography using 68 gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.

Using 18 F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

The SEMITEP investigators postulated that 18 F-fluorodeoxyglucose–positron emission tomography (FDG–PET) could help “identify patients with highly chemosensitive disease at an early stage,” thereby sparing the majority from receiving unnecessary treatments.

The researchers note in JAMA Oncology that 44% of patients treated with SABR had baseline positron emission tomography (PET)-avid lesions that were not included in the treatment fields because the researchers were blinded to prostate-specific membrane antigen (PSMA)-targeted PET data during treatment planning.

Researchers do not recommend the addition of 18 F-fluorodeoxyglucose–positron emission tomography/computed tomography to a standard 3-year monitoring strategy for patients with stage II perforated, stage III, or stage IV colorectal cancer at high risk for recurrence.

A negative positron emission tomography scan after initial treatment with BEACOPP in escalated doses identifies Hodgkin lymphoma patients suitable for a reduction in the total number of cycles needed, HD18 trial data show.

The researchers calculated that 154 LDCT and 1.4 positron emission tomography (PET) scans, used selectively for differential diagnosis, were required to identify one case of lung cancer.